College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, People's Republic of China.
Nanoscale. 2015 Sep 14;7(34):14538-46. doi: 10.1039/c5nr04003e.
We report a convenient approach to prepare ultrasmall Fe3O4 nanoparticles (NPs) functionalized with an arginylglycylaspartic acid (RGD) peptide for in vitro and in vivo magnetic resonance (MR) imaging of gliomas. In our work, stable sodium citrate-stabilized Fe3O4 NPs were prepared by a solvothermal route. Then, the carboxylated Fe3O4 NPs stabilized with sodium citrate were conjugated with polyethylene glycol (PEG)-linked RGD. The formed ultrasmall RGD-functionalized nanoprobe (Fe3O4-PEG-RGD) was fully characterized using different techniques. We show that these Fe3O4-PEG-RGD particles with a size of 2.7 nm are water-dispersible, stable, cytocompatible and hemocompatible in a given concentration range, and display targeting specificity to glioma cells overexpressing αvβ3 integrin in vitro. With the relatively high r1 relaxivity (r1 = 1.4 mM(-1) s(-1)), the Fe3O4-PEG-RGD particles can be used as an efficient nanoprobe for targeted T1-weighted positive MR imaging of glioma cells in vitro and the xenografted tumor model in vivo via an active RGD-mediated targeting pathway. The developed RGD-functionalized Fe3O4 NPs may hold great promise to be used as a nanoprobe for targeted T1-weighted MR imaging of different αvβ3 integrin-overexpressing cancer cells or biological systems.
我们报道了一种方便的方法,可制备精氨酸-甘氨酰-天冬氨酸(RGD)肽功能化的超小 Fe3O4 纳米颗粒(NPs),用于体外和体内脑胶质瘤的磁共振(MR)成像。在我们的工作中,通过溶剂热法制备了稳定的柠檬酸根稳定的 Fe3O4 NPs。然后,用柠檬酸根稳定的羧基化 Fe3O4 NPs 与聚乙二醇(PEG)连接的 RGD 偶联。通过不同的技术对形成的超小 RGD 功能化纳米探针(Fe3O4-PEG-RGD)进行了全面的表征。我们表明,这些尺寸为 2.7nm 的 Fe3O4-PEG-RGD 颗粒在给定浓度范围内具有水分散性、稳定性、细胞相容性和血液相容性,并且在体外对过表达αvβ3 整合素的神经胶质瘤细胞具有靶向特异性。由于具有相对较高的 r1 弛豫率(r1 = 1.4 mM-1 s-1),因此 Fe3O4-PEG-RGD 颗粒可用作体外靶向 T1 加权正磁共振成像的有效纳米探针,以及体内异种移植肿瘤模型。所开发的 RGD 功能化 Fe3O4 NPs 有望用作针对不同过表达αvβ3 整合素的癌细胞或生物系统的靶向 T1 加权 MR 成像的纳米探针。
ACS Appl Mater Interfaces. 2015-3-11
Nanomaterials (Basel). 2024-12-28
Chem Biomed Imaging. 2023-5-4
Mol Cancer. 2023-5-25